A citation-based method for searching scientific literature

Bruce A Perkins, Julio Rosenstock, Jay S Skyler, Lori M Laffel, David Z Cherney, Chantal Mathieu, Christianne Pang, Richard Wood, Ona Kinduryte, Jyothis T George, Jan Marquard, Nima Soleymanlou. Diabetes Care 2019
Times Cited: 8







List of co-cited articles
60 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes.
Daniël H van Raalte, Petter Bjornstad, Frederik Persson, David R Powell, Rita de Cassia Castro, Ping Stella Wang, Minzhi Liu, Hiddo J L Heerspink, David Cherney. Diabetes Care 2019
23
75

Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
John B Buse, Satish K Garg, Julio Rosenstock, Timothy S Bailey, Phillip Banks, Bruce W Bode, Thomas Danne, Jake A Kushner, Wendy S Lane, Pablo Lapuerta,[...]. Diabetes Care 2018
113
62

Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
Satish K Garg, Robert R Henry, Phillip Banks, John B Buse, Melanie J Davies, Gregory R Fulcher, Paolo Pozzilli, Diane Gesty-Palmer, Pablo Lapuerta, Rafael Simó,[...]. N Engl J Med 2017
226
62

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
62

Empagliflozin as Adjunctive to Insulin Therapy in Type 1 Diabetes: The EASE Trials.
Julio Rosenstock, Jan Marquard, Lori M Laffel, Dietmar Neubacher, Stefan Kaspers, David Z Cherney, Bernard Zinman, Jay S Skyler, Jyothis George, Nima Soleymanlou,[...]. Diabetes Care 2018
144
62

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes (the DEPICT-2 Study): 24-Week Results From a Randomized Controlled Trial.
Chantal Mathieu, Paresh Dandona, Pieter Gillard, Peter Senior, Christoph Hasslacher, Eiichi Araki, Marcus Lind, Stephen C Bain, Serge Jabbour, Niki Arya,[...]. Diabetes Care 2018
143
62

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
62

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
62

HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study.
Thomas Danne, Bertrand Cariou, Phillip Banks, Michael Brandle, Helmut Brath, Edward Franek, Jake A Kushner, Pablo Lapuerta, Darren K McGuire, Anne L Peters,[...]. Diabetes Care 2018
93
50

Efficacy and Safety of Dapagliflozin in Patients With Inadequately Controlled Type 1 Diabetes: The DEPICT-1 52-Week Study.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Diabetes Care 2018
112
50


Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.
Thomas Danne, Bertrand Cariou, John B Buse, Satish K Garg, Julio Rosenstock, Phillip Banks, Jake A Kushner, Darren K McGuire, Anne L Peters, Sangeeta Sawhney,[...]. Diabetes Care 2019
39
37

Current state of type 1 diabetes treatment in the U.S.: updated data from the T1D Exchange clinic registry.
Kellee M Miller, Nicole C Foster, Roy W Beck, Richard M Bergenstal, Stephanie N DuBose, Linda A DiMeglio, David M Maahs, William V Tamborlane. Diabetes Care 2015
863
37

International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors.
Thomas Danne, Satish Garg, Anne L Peters, John B Buse, Chantal Mathieu, Jeremy H Pettus, Charles M Alexander, Tadej Battelino, F Javier Ampudia-Blasco, Bruce W Bode,[...]. Diabetes Care 2019
151
37

The effect of empagliflozin on arterial stiffness and heart rate variability in subjects with uncomplicated type 1 diabetes mellitus.
David Zi Cherney, Bruce A Perkins, Nima Soleymanlou, Ronnie Har, Nora Fagan, Odd Erik Johansen, Hans-Juergen Woerle, Maximilian von Eynatten, Uli C Broedl. Cardiovasc Diabetol 2014
335
37

Evaluation of Glomerular Hemodynamic Function by Empagliflozin in Diabetic Mice Using In Vivo Imaging.
Kengo Kidokoro, David Z I Cherney, Andrea Bozovic, Hajime Nagasu, Minoru Satoh, Eiichiro Kanda, Tamaki Sasaki, Naoki Kashihara. Circulation 2019
137
37

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
37

Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
Paresh Dandona, Chantal Mathieu, Moshe Phillip, Lars Hansen, Steven C Griffen, Diethelm Tschöpe, Fredrik Thorén, John Xu, Anna Maria Langkilde. Lancet Diabetes Endocrinol 2017
179
37


Glycaemic control of Type 1 diabetes in clinical practice early in the 21st century: an international comparison.
J A McKnight, S H Wild, M J E Lamb, M N Cooper, T W Jones, E A Davis, S Hofer, M Fritsch, E Schober, J Svensson,[...]. Diabet Med 2015
212
25

LX4211, a dual SGLT1/SGLT2 inhibitor, improved glycemic control in patients with type 2 diabetes in a randomized, placebo-controlled trial.
B Zambrowicz, J Freiman, P M Brown, K S Frazier, A Turnage, J Bronner, D Ruff, M Shadoan, P Banks, F Mseeh,[...]. Clin Pharmacol Ther 2012
175
25

Acute Effect of Empagliflozin on Fractional Excretion of Sodium and eGFR in Youth With Type 2 Diabetes.
Petter Bjornstad, Lori Laffel, William V Tamborlane, Gudrun Simons, Stefan Hantel, Maximilian von Eynatten, Jyothis George, Jan Marquard, David Z I Cherney. Diabetes Care 2018
22
25

Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus.
David Z I Cherney, Bruce A Perkins, Nima Soleymanlou, Maria Maione, Vesta Lai, Alana Lee, Nora M Fagan, Hans J Woerle, Odd Erik Johansen, Uli C Broedl,[...]. Circulation 2014
827
25

SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis.
Brendon L Neuen, Tamara Young, Hiddo J L Heerspink, Bruce Neal, Vlado Perkovic, Laurent Billot, Kenneth W Mahaffey, David M Charytan, David C Wheeler, Clare Arnott,[...]. Lancet Diabetes Endocrinol 2019
371
25

Risk of Diabetic Ketoacidosis after Initiation of an SGLT2 Inhibitor.
Michael Fralick, Sebastian Schneeweiss, Elisabetta Patorno. N Engl J Med 2017
166
25

Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: Real-world data analysis.
Avivit Cahn, Cheli Melzer-Cohen, Rena Pollack, Gabriel Chodick, Varda Shalev. Diabetes Obes Metab 2019
49
25


Dapagliflozin in focal segmental glomerulosclerosis: a combined human-rodent pilot study.
Harindra Rajasekeran, Heather N Reich, Michelle A Hladunewich, Daniel Cattran, Julie A Lovshin, Yuliya Lytvyn, Petter Bjornstad, Vesta Lai, Josephine Tse, Leslie Cham,[...]. Am J Physiol Renal Physiol 2018
49
25



Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes.
Christoph Wanner, Silvio E Inzucchi, John M Lachin, David Fitchett, Maximilian von Eynatten, Michaela Mattheus, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Bernard Zinman. N Engl J Med 2016
25

Pooled analysis of Phase III trials indicate contrasting influences of renal function on blood pressure, body weight, and HbA1c reductions with empagliflozin.
David Z I Cherney, Mark E Cooper, Ilkka Tikkanen, Egon Pfarr, Odd Erik Johansen, Hans J Woerle, Uli C Broedl, Søren S Lund. Kidney Int 2018
111
25


How Does Empagliflozin Reduce Cardiovascular Mortality? Insights From a Mediation Analysis of the EMPA-REG OUTCOME Trial.
Silvio E Inzucchi, Bernard Zinman, David Fitchett, Christoph Wanner, Ele Ferrannini, Martin Schumacher, Claudia Schmoor, Kristin Ohneberg, Odd Erik Johansen, Jyothis T George,[...]. Diabetes Care 2018
412
25

Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial.
David Z I Cherney, Bernard Zinman, Silvio E Inzucchi, Audrey Koitka-Weber, Michaela Mattheus, Maximilian von Eynatten, Christoph Wanner. Lancet Diabetes Endocrinol 2017
220
25

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
25

Effects of the SGLT-2 inhibitor dapagliflozin on glomerular and tubular injury markers.
Claire C J Dekkers, Sergei Petrykiv, Gozewijn D Laverman, David Z Cherney, Ron T Gansevoort, Hiddo J L Heerspink. Diabetes Obes Metab 2018
129
25

Sodium-glucose cotransporter 2 inhibition and glycemic control in type 1 diabetes: results of an 8-week open-label proof-of-concept trial.
Bruce A Perkins, David Z I Cherney, Helen Partridge, Nima Soleymanlou, Holly Tschirhart, Bernard Zinman, Nora M Fagan, Stefan Kaspers, Hans-Juergen Woerle, Uli C Broedl,[...]. Diabetes Care 2014
173
25

Canagliflozin Prevents Intrarenal Angiotensinogen Augmentation and Mitigates Kidney Injury and Hypertension in Mouse Model of Type 2 Diabetes Mellitus.
T Cooper Woods, Ryousuke Satou, Kayoko Miyata, Akemi Katsurada, Courtney M Dugas, Natasha C Klingenberg, Vivian A Fonseca, L Gabriel Navar. Am J Nephrol 2019
61
25

Antihyperglycemic agents as novel natriuretic therapies in diabetic kidney disease.
David León Jiménez, David Z I Cherney, Petter Bjornstad, Luis Castilla-Guerra, José Pablo Miramontes González. Am J Physiol Renal Physiol 2018
18
25

Molecular regulation of the renin-angiotensin system by sodium-glucose cotransporter 2 inhibition in type 1 diabetes mellitus.
Chantal Kopecky, Yuliya Lytvyn, Oliver Domenig, Marlies Antlanger, Johannes J Kovarik, Christopher C Kaltenecker, Marko Poglitsch, Bruce A Perkins, Kerry-Anne Rye, David Z I Cherney,[...]. Diabetologia 2019
15
25


The effect of sodium glucose cotransporter 2 inhibition with empagliflozin on microalbuminuria and macroalbuminuria in patients with type 2 diabetes.
David Cherney, Søren S Lund, Bruce A Perkins, Per-Henrik Groop, Mark E Cooper, Stefan Kaspers, Egon Pfarr, Hans J Woerle, Maximilian von Eynatten. Diabetologia 2016
114
25

The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.
Erik J M van Bommel, Marcel H A Muskiet, Michaël J B van Baar, Lennart Tonneijck, Mark M Smits, Anna L Emanuel, Andrea Bozovic, A H Jan Danser, Frank Geurts, Ewout J Hoorn,[...]. Kidney Int 2020
151
25

Use of Adjuvant Pharmacotherapy in Type 1 Diabetes: International Comparison of 49,996 Individuals in the Prospective Diabetes Follow-up and T1D Exchange Registries.
Sarah K Lyons, Julia M Hermann, Kellee M Miller, Sabine E Hofer, Nicole C Foster, Birgit M Rami-Merhar, Grazia Aleppo, Jochen Seufert, Linda A DiMeglio, Thomas Danne,[...]. Diabetes Care 2017
34
25


SGLT inhibitor adjunct therapy in type 1 diabetes.
Rory J McCrimmon, Robert R Henry. Diabetologia 2018
49
25


Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.
Anne L Peters, Elizabeth O Buschur, John B Buse, Pejman Cohan, Jamie C Diner, Irl B Hirsch. Diabetes Care 2015
474
25

Sotagliflozin Decreases Postprandial Glucose and Insulin Concentrations by Delaying Intestinal Glucose Absorption.
David R Powell, Brian Zambrowicz, Linda Morrow, Carine Beysen, Marcus Hompesch, Scott Turner, Marc Hellerstein, Phillip Banks, Paul Strumph, Pablo Lapuerta. J Clin Endocrinol Metab 2020
23
25


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.